Company Profile We are the leading company in RNA-targeted drug discovery and development, exploiting a proven novel drug discovery platform we created to generate a broad pipeline of first-in-class or best-in-class antisense drugs. The efficiency and broad applicability of our drug discovery platform allows us to discover and develop antisense drugs to treat a wide range of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. The efficiency of our drug discovery technology allows us to employ a unique business strategy designed to maximize the value of our drugs and technology while maintaining an effective cost structure that limits our cash needs. Our business strategy is supported by our platform technology, our robust pipeline of drugs and our multifaceted partnering strategy, which have enabled us to focus on doing what we do best - to discover and develop novel antisense drugs.
CARLSBAD, Calif., May 28, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:
Akcea Therapeutics Webcast
Thursday, June 4 at 1:00 p.m. ET / 10:00 a.m. PT
Live on the Internet. Simply log onto our website listed above.
If you are unable to participate duri...
- Pro Forma Operating Income Driven by $46 Million in Partner Payments
- Conference Call Webcast Tuesday, May 5, 11:30 a.m. ET at www.isispharm.com
CARLSBAD, Calif., May 5, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported pro forma operating income of $4.0 million for the three months ended March 31, 2015 compared to a pro forma net operating loss of $22.6 million for the same period in 2014. Isis' significantly improved financial results were due to higher re...
--Bayer to develop ISIS-FXI Rx broadly for the prevention of thrombosis--
--Transaction maximizes value of the ISIS-FXI Rx program--
--Partnership provides Isis with significant potential to participate in commercial success of ISIS-FXI Rx--
CARLSBAD, Calif., May 4, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) has entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention of thrombo...
CARLSBAD, Calif., April 30, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed target to treat a neurological disorder. This is the ninth program to advance, which includes four drugs in development, under Isis' and Biogen's broad strategic alliance to discover and develop novel therapies to treat neurological and neuromuscular disorders.
"Together with B...